Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol
Optimizing 6-mercaptopurine Therapy in Pediatric Acute Lymphoblastic Leukemia by Using Allopurinol Clinical Study in Children 1-19 Years on Maintenance Therapy for Acute Lymphoblastic Leukemia.
Sponsor: Vastra Gotaland Region
A PHASE2 clinical study on Lymphoblastic Leukemia, Acute, Childhood, this trial is ongoing. The trial is conducted by Vastra Gotaland Region and has accumulated 6 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
May 2019 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vastra Gotaland Region
For direct contact, visit the study record on ClinicalTrials.gov .